Last reviewed · How we verify
Alprolix
At a glance
| Generic name | Alprolix |
|---|---|
| Also known as | Eftrenonacog alfa, rFIXFc, Eftrenonacog alfa, rFIXFc |
| Sponsor | Swedish Orphan Biovitrum |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Hereditary factor IX deficiency disease
Common side effects
- Headache
- Oral paresthesia
- Obstructive uropathy
- Injection site erythema
- Hypersensitivity
Serious adverse events
- Factor IX inhibition
Key clinical trials
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
- Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)
- A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (PHASE1)
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (PHASE3)
- ATHN 2: Factor Switching Study
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alprolix CI brief — competitive landscape report
- Alprolix updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI